Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients

0576728 - MBÚ 2024 RIV CH eng J - Článek v odborném periodiku
Kosztyu, P. - Hill, M. - Jemelková, J. - Czerneková, L. - Kafková, L.R. - Hrubý, M. - Matoušovic, K. - Vondrák, K. - Zadražil, J. - Šterzl, I. - Městecký, Jiří - Raška, M.
Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients.
Kidney & Blood Pressure Research. Roč. 43, č. 2 (2018), s. 350-359. ISSN 1420-4096. E-ISSN 1423-0143
Grant CEP: GA MZd(CZ) NV15-33686A
Klíčová slova: Iga nephropathy * O-glycosylation * IgA1 hinge region * Circulating immune complexes * Galactose deficiency * Glycan-specific antibodies
Obor OECD: Microbiology
Impakt faktor: 2.123, rok: 2018
Způsob publikování: Open access
https://karger.com/kbr/article/43/2/350/187867/Glucocorticoids-Reduce-Aberrant-O-Glycosylation-of

Background/Aims: IgA nephropathy is associated with aberrant O-glycosylation of IgA1, which is recognized by autoantibodies leading to the formation of circulating immune complexes. Some of them, after deposition into kidney mesangium, trigger glomerular injury. In patients with active disease nonresponding to angiotensin-converting enzyme inhibitors or angiotensin II blockers, corticosteroids are recommended. Methods: The relationship between the corticosteroid therapy and serum levels of IgA, aberrantly O-glycosylated IgA1, IgA-containing immune complexes and their mesangioproliferative activity was analyzed in IgA nephropathy patients and disease and healthy controls. Results: Prednisone therapy significantly reduced proteinuria and levels of serum IgA, galactose-deficient IgA1, and IgA-IgG immune complexes in IgA nephropathy patients and thus reduced differences in all of the above parameters between IgAN patients and control groups. A moderate but not significant reduction of mesangioproliferative potential of IgA-IgG immune complexes and IgA sialylation was detected. Conclusion: The prednisone therapy reduces overall aberrancy in IgA1 O-glycosylation in IgA nephropathy patients, but the measurement of IgA1 parameters does not allow us to predict the prednisone therapy outcome in individual patients. (C) 2018 The Author(s) Published by S. Karger AG, Basel.
Trvalý link: https://hdl.handle.net/11104/0346157